British Thoracic Society

GSK announces largest private financial contribution to CIHR's Team Grants initiative addressing threats to Canadian lung health

Retrieved on: 
화요일, 9월 26, 2023
Heart, GSK, British Thoracic Society, Canadian Thoracic Society, Atmosphere, Gas, Wildfire, Overalls, Water quality, International Workshop on Lung Health, COVID-19, Radon, Woman, Public, CIHR, Research, Brain, Inhalation, Lung cancer in Australia, History, Lung, Indigenous peoples, Death, Climate change, Patient, Risk, Canadian Institutes of Health Research, Viral, Health, Smoking, Air pollution, Virus, Herbal cigarette, Pharmaceutical industry, MISSISSAUGA

The funds will be managed and administered by the Canadian Institutes of Health Research (CIHR) through the Team Grants in Lung Health initiative.

Key Points: 
  • The funds will be managed and administered by the Canadian Institutes of Health Research (CIHR) through the Team Grants in Lung Health initiative.
  • GSK's contribution is the largest private financial contribution to this research initiative to date.
  • GSK is investing $2 million in research to address ongoing, new, and emerging threats to lung health in Canada.
  • Considering these and other significant threats to lung health, such as lung cancers, the effects of vaping on health, viral infections such as COVID-19, and the impacts of climate change, there is an urgent need for strategic investment in lung health research.1
    "The CIHR's Team Grants in Lung Health is the single largest investment in lung health research in the history of CIHR.

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile

Retrieved on: 
목요일, 3월 23, 2023
British Thoracic Society, Diarrhea, HRCT, Respiratory rate, Aes, FVC, Life expectancy, Cough, Rash, Vomiting, Fibrosis, Incidence, Patient, BID, Spirometry, St Thomas' Hospital, Nausea, Periodic breathing, Oxygen toxicity, Guy, Hospital, Guy Henry Faget, Upper respiratory tract infection, IPF, Idiopathic pulmonary fibrosis, Safety, Fatigue, ATLAS, Pharmaceutical industry, Thorax

The study assessed safety and efficacy of AP01 (inhaled pirfenidone) in adults with idiopathic pulmonary fibrosis (IPF) through 72 weeks.

Key Points: 
  • The study assessed safety and efficacy of AP01 (inhaled pirfenidone) in adults with idiopathic pulmonary fibrosis (IPF) through 72 weeks.
  • Efficacy and safety results at weeks 24 and 48 are also reported.
  • “While oral pirfenidone has the potential to improve lung function by reducing fibrosis, its utility is limited by its poor tolerability profile,” explained Lyn Baranowski, Avalyn’s CEO .
  • “Although the ATLAS study's primary endpoint was safety, secondary measures of efficacy showed a trend towards disease stabilization in participants with IPF who administered high-dose AP01.

Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting

Retrieved on: 
목요일, 10월 27, 2022
Idiopathic pulmonary fibrosis, IPF, Winter Meeting, British Thoracic Society, Chronic cough, Therapy, Patient, Quality of life, MD, Caregiver, Fatigue, National Heart, Lung, and Blood Institute, Nasdaq, Nalbuphine, Cough, Medical school, BTS, Pharmaceutical industry, HAVEN

NEW HAVEN, Conn., Oct. 27, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of serious chronic cough conditions, today announced data from the full set of subjects from CANAL, a phase 2 trial in idiopathic pulmonary fibrosis (IPF) chronic cough, will be presented as an oral presentation at the upcoming British Thoracic Society's (BTS) Winter Meeting 2022 taking place in London, United Kingdom.

Key Points: 
  • The CANAL (Cough And NALbuphine) trial was a Phase 2 double-blind, randomized, placebo-controlled, 2-treatment, 2-period crossover efficacy and safety study of nalbuphine ER for chronic cough in IPF.
  • There are no approved therapies for the treatment of chronic cough in IPF and the cough often isn't affected by antitussive therapy.
  • The Company has successfully completed a Phase 2 trial of Haduvio for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF).
  • Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).

Seventy Percent (70%) of Patients Surveyed Voice Concern About Tobacco Corporations’ Ownership of Lung Disease Treatments

Retrieved on: 
월요일, 8월 15, 2022
Tobacco, Health, General Health, Healthcare Reform, Public Policy, Seniors, Research, Retail, Public Policy, Government, Consumer, Science, Linda, Health insurance coverage in the United States, Smoker, PMI, Chronic lung disease, CEO, Asthma, Philip Morris International, Winders, Sale, Smoking, British Thoracic Society, Chronic obstructive pulmonary disease, Caregiver, Research, Human, Foundation, Patient, Twitter, Education, Degenerative disease, NTM, Awareness, COPD, Doctor of Philosophy, Bronchiectasis, Respiratory disease, Ownership, Journal, MD, LinkedIn, Disease, Pharmaceutical industry, Health insurance, Medicine, Thorax, Vectura Group

The survey gave people with chronic lung disease a voice in the conversation about tobacco corporations owning companies that develop tools and medications to treat lung conditions.

Key Points: 
  • The survey gave people with chronic lung disease a voice in the conversation about tobacco corporations owning companies that develop tools and medications to treat lung conditions.
  • Based on the surveys findings, as reported in Thorax, most patients care deeply that tobacco companies have a financial stake in drug or device companies and profit from life-saving treatment.
  • Vectura develops several widely used medical delivery devices and/or formulations for inhaled therapies used in people with chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma.
  • It is morally wrong,
    They made lots of money; they should research and develop treatments for those that used their products.

Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein

Retrieved on: 
목요일, 7월 7, 2022
COVID-19, Infectious Diseases, Hospitals, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Annals of the American Thoracic Society, Patient, British Thoracic Society, CRP, Nasdaq, Pharmaceutical industry, Thorax, COVID-19, Infectious Diseases, Hospitals, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health

Lenzilumab binds to and neutralizes GM-CSF, potentially improving outcomes for patients hospitalized with COVID-19.

Key Points: 
  • Lenzilumab binds to and neutralizes GM-CSF, potentially improving outcomes for patients hospitalized with COVID-19.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.
  • C-reactive protein, a biomarker for early lenzilumab treatment of COVID-19, improves efficacy: a sub-analysis of the randomized phase 3 LIVE-AIR trial.
  • https://doi.org/10.1016/S2213-2600(21)00494-X
    Humaneered is a trademark of Humanigen, Inc.
    Yescarta and Tecartus are trademarks of Gilead Sciences, Inc., or its related companies.

The COVID-19 Respiratory Roundtable Issues Joint Letter Urging Canadians to Continue Protecting Each Other

Retrieved on: 
토요일, 4월 23, 2022
Knowledge, Canadian Thoracic Society, COVID-19, Round Table, Research, Knowledge sharing, MASK, Degenerative disease, Leadership, Learning, Pandemic fatigue, Organization, Critical care, LOVE, British Thoracic Society, COVID, CTS, Fatigue, Animal, Pharmaceutical industry, Hospital

Ottawa, Ontario--(Newsfile Corp. - April 23, 2022) - The COVID-19 Respiratory Roundtable has released a joint letter, MASK UP FOR SOMEONE YOU LOVE , urging Canadians to continue taking precautions amidst the easing of public health guidelines.

Key Points: 
  • Ottawa, Ontario--(Newsfile Corp. - April 23, 2022) - The COVID-19 Respiratory Roundtable has released a joint letter, MASK UP FOR SOMEONE YOU LOVE , urging Canadians to continue taking precautions amidst the easing of public health guidelines.
  • The Respiratory Roundtable's joint letter provides a summary of the risks that COVID-19 poses and provides a number of precautionary measures that can empower greater protection for Canadians.
  • In April 2020, the Canadian Thoracic Society (CTS) brought together a group of professional societies and patient organizations from across Canada to form the COVID-19 Respiratory Roundtable.
  • The Roundtable meets monthly to exchange information on pandemic-related activities and strategies, align messaging and identify opportunities for collaboration.

Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021

Retrieved on: 
월요일, 11월 22, 2021
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, 2021 Essex County Council election, Government, British Thoracic Society, CEO, C-reactive protein, Death, MD, CRP, Pulmonary alveolar proteinosis, COVID-19, Nasdaq, Chief executive officer, Incidence, Nursing, United Kingdom, Randomness, Pharmaceutical industry, ISARIC Coronavirus Clinical Characterisation Consortium (4C) Mortality Score, Humanigen, Inc., ISARIC CORONAVIRUS CLINICAL CHARACTERISATION CONSORTIUM (4C) MORTALITY SCORE, HUMANIGEN, INC.

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced three abstracts pertaining to the potential use of lenzilumab in hospitalized COVID-19 patients will be presented at the British Thoracic Society Winter 2021 Meeting taking place Nov. 24-26, 2021.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced three abstracts pertaining to the potential use of lenzilumab in hospitalized COVID-19 patients will be presented at the British Thoracic Society Winter 2021 Meeting taking place Nov. 24-26, 2021.
  • The society counts more than 4,000 members comprised of doctors, nurses, respiratory physiotherapists, scientists, and other professionals with a respiratory interest.
  • The study also demonstrated significant improvement in SWOV for the predefined subgroup of subjects who received both corticosteroids and remdesivir (HR: 1.92; nominal p=0.0067).
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.

CohBar’s Abstract for the American Thoracic Society 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine

Retrieved on: 
금요일, 5월 1, 2020
Respiratory therapy, Medicine, Health, Animal physiology, American Thoracic Society, Pulmonology, Breathing, British Thoracic Society

The American Thoracic Society is the world's leading medical association dedicated to advancing clinical and scientific understanding of pulmonary diseases, critical illnesses and sleep-related breathing disorders.

Key Points: 
  • The American Thoracic Society is the world's leading medical association dedicated to advancing clinical and scientific understanding of pulmonary diseases, critical illnesses and sleep-related breathing disorders.
  • Today, it has grown into an international society with more than 16,000 members.
  • The conference, which was scheduled to be held May 15-20 in Philadelphia, PA, has been cancelled.
  • The American Thoracic Society is currently exploring options for providing select elements of the conference content including ePosters in an online format later this year.